CRISPR Therapeutics AG Quarterly Net Cash Provided by (Used in) Investing Activities in USD from Q1 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Summary
CRISPR Therapeutics AG quarterly/annual Net Cash Provided by (Used in) Investing Activities history and growth rate from Q1 2018 to Q1 2024.
  • CRISPR Therapeutics AG Net Cash Provided by (Used in) Investing Activities for the quarter ending March 31, 2024 was -$97.8M, a 183% decline year-over-year.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Investing Activities for 2023 was $375M.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Investing Activities for 2022 was -$259M, a 75% increase from 2021.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Investing Activities for 2021 was -$1.04B, a 91.3% decline from 2020.
Net Cash Provided by (Used in) Investing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$97.8M -$216M -183% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q1 2023 $118M +$232M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 -$115M +$53.4M +31.8% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-09
Q1 2021 -$168M -$165M -5513% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 -$2.99M -$1.89M -173% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q1 2019 -$1.1M -$542K -97.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q1 2018 -$555K Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.